Free Trial

Standard BioTools (LAB) 10K Form and Latest SEC Filings 2026

Standard BioTools logo
$0.98 -0.02 (-1.87%)
As of 01:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Standard BioTools SEC Filings & Recent Activity

Standard BioTools (NASDAQ:LAB) has submitted 576+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Standard BioTools's financial statements. The most recent filing was a Form ARS submitted on April 27, 2026.

Form 4
STANDARD BIOTOOLS INC. Reports Ownership Change on Apr. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Standard BioTools Files Current Report on Apr. 24, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Standard BioTools Files Quarterly Report on Nov. 4, 2025

The 10-Q contains Standard BioTools's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Standard BioTools SEC Filing History

Browse Standard BioTools' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/27/2026 3:15 PM
Standard BioTools (1162194) Filer
Form DEF 14A
04/27/2026 3:17 PM
Standard BioTools (1162194) Filer
Form DEFA14A
04/27/2026 3:20 PM
Standard BioTools (1162194) Filer
Form ARS
04/24/2026 3:15 PM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2026 8:55 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 8:55 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/08/2026 8:55 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 7:02 PM
Casdin Eli (1534264) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:31 PM
Carey Thomas D. (1574633) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:32 PM
Cox Troy (1696923) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 4:44 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 4:44 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 4:45 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 8:18 AM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 6:10 AM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 4:42 PM
MAK Capital Fund LP (1426156) Filed by
Standard BioTools (1162194) Subject
Form SCHEDULE 13G
12/04/2025 7:59 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 4:33 PM
Casdin Capital, LLC (1534261) Filed by
Standard BioTools (1162194) Subject
Form SCHEDULE 13D/A
11/24/2025 4:03 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 4:04 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 4:05 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 6:45 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/17/2025 5:58 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 6:46 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 3:10 PM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2025 3:11 PM
Standard BioTools (1162194) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/11/2025 8:03 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 6:08 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 5:05 AM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/26/2025 7:46 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 4:45 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 4:45 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 4:46 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2025 8:18 PM
Casdin Capital, LLC (1534261) Reporting
Casdin Eli (1534264) Reporting
Casdin Partners GP, LLC (1534260) Reporting
Casdin Partners Master Fund, L.P. (1534265) Reporting
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (1864554) Reporting
Casdin Private Growth Equity Fund II GP, LLC (1919480) Reporting
Casdin Private Growth Equity Fund II, L.P. (1891102) Reporting
Casdin Private Growth Equity Fund, L.P. (1823061) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2025 5:23 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2025 5:33 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2025 7:10 PM
Cox Troy (1696923) Reporting
Standard BioTools (1162194) Issuer
Form 4/A
06/24/2025 6:00 PM
Cox Troy (1696923) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:57 PM
Casdin Eli (1534264) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:58 PM
Carey Thomas D. (1574633) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:58 PM
ELOI FENEL M (1237190) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel

06/24/2025 5:53 PM
Standard BioTools (1162194) Issuer
Witney Frank (1455312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/24/2025 5:55 PM
HIBBS KATHY L (1267487) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 8:11 AM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2025 3:16 PM
Standard BioTools (1162194) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/30/2025 4:48 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2025 4:48 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2025 4:52 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:54 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:44 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:52 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 7:33 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025 7:28 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 5:13 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:09 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/22/2025 7:01 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 7:03 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 3:20 PM
Egholm Michael (1559779) Reporting
Standard BioTools (1162194) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/21/2025 3:16 PM
Mackay Sean (1875501) Reporting
Standard BioTools (1162194) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/21/2025 3:22 PM
Kim Hanjoon Alex (1919209) Reporting
Standard BioTools (1162194) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Standard BioTools SEC Filings - Frequently Asked Questions

Standard BioTools (LAB) has submitted 576+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Standard BioTools's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Standard BioTools's financial statements page.

The most recent filing was a Form ARS submitted on April 27, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:LAB) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners